IO Biotech compared its vaccine to Merck & Co.'s Keytruda.

1 report, 1 independent Updated Aug 11

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Merck KGaA

Keep exploring

Part of

IO Biotech is trialing Cylembio in combination with Merck's anti-PD-1 therapy. All 1 developments

The entities involved

Merck KGaA
German multinational science and technology company
- MSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.Mon 12:02
- Merck KGaA filed required 13F reports with the Securities and Exchange Commission regarding institutional holdings on June 15, 2026.Mon 02:05

Related events

Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.Jun 7

Coverage

Newest first; wire copies grouped

Aug 11BioPharma DiveIO Biotech sees path forward for skin cancer vaccine despite study setback This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPh